Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna

With an annual dividend yield of 2.85%, Amgen Inc. (NASDAQ:AMGN) is included among the 12 High Yield Fortune 500 Stocks to Buy Now.

Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases.

On June 10, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) from $322 to $340, while keeping an ‘Equal Weight’ rating on the shares. The boosted price goal still indicates a downside of over 4% from the current levels.

The US Food and Drug Administration (FDA) approved Amgen’s Uplizna as the first treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD) last year.  The drug was later also approved by the European Commission as an add-on treatment to standard therapy for adults living with generalized myasthenia gravis (gMG) in February 2026.

Morgan Stanley noted that the launch of Uplizna for generalized myasthenia gravis (gMG) is “off to a strong start”. The firm believes that the gMG market has the potential to double to over $10 billion over the next five or so years, fueled by the introduction of new therapies and the rising adoption of biologics.

While we acknowledge the risk and potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High Yield Crude Oil Stocks to Buy Now and 10 Most Volatile Stocks to Buy in S&P 500

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1